BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5740
- TODAY'S CHANGE (%)0.0379 (7.0696%)
- Bid / Lots0.5740/ 1
- Ask / Lots0.5870/ 4
- Open / Previous Close0.5990 / 0.5361
- Day Range
- 52 Week Range
- Volume127,378
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 9127 | 0.5926 |
| 09:34 ET | 100 | 0.5897 |
| 09:36 ET | 9315 | 0.59 |
| 09:38 ET | 2600 | 0.59 |
| 09:39 ET | 5016 | 0.59005 |
| 09:41 ET | 17333 | 0.5889 |
| 09:45 ET | 8403 | 0.574 |
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.6M | -0.8x | --- |
Cue Biopharma Inc | 45.6M | -0.7x | --- |
Kronos Bio Inc | 60.3M | -0.6x | --- |
Kezar Life Sciences Inc | 56.4M | -0.6x | --- |
LAVA Therapeutics NV | 43.6M | -1.8x | --- |
Adlai Nortye Ltd | 73.2M | -0.3x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
